+

PE20020366A1 - Derivados de piperazina como ligandos del receptor 5ht2 - Google Patents

Derivados de piperazina como ligandos del receptor 5ht2

Info

Publication number
PE20020366A1
PE20020366A1 PE2001000749A PE2001000749A PE20020366A1 PE 20020366 A1 PE20020366 A1 PE 20020366A1 PE 2001000749 A PE2001000749 A PE 2001000749A PE 2001000749 A PE2001000749 A PE 2001000749A PE 20020366 A1 PE20020366 A1 PE 20020366A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
receptor
piperazine derivatives
pirazino
Prior art date
Application number
PE2001000749A
Other languages
English (en)
Inventor
Jonathan Mark Bentley
Paul Hebeisen
Marc Muller
Hans Richter
Stephan Roever
Patrizio Mattei
Sven Taylor
Original Assignee
Vernalis Res Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd, Hoffmann La Roche filed Critical Vernalis Res Ltd
Publication of PE20020366A1 publication Critical patent/PE20020366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIPERAZINA DONDE R1, R2, R3, R4 SON H, HALOGENO, OH, ALQUILO, CICLOALQUILO, ARALQUILO, ARILO, ALCOXI; O R3 Y R4 JUNTO A C FORMAN UN ANILLO CARBOCICLICO DE 5-7 MIEMBROS OPCIONALMENTE SUSTITUIDO POR ALQUILO; R5 Y R8 SON H, ALQUILO, CICLOALQUILO; R6 ES H, ALQUILO, CICLOALQUILO, HIDROXIALQUILO, CARBAMOILALQUILO, ENTRE OTROS; R7 ES H, ALQUILO, CICLOALQUILO, ALCOXIALQUILO; A ES HETEROCICLO, CICLOALCANOILO, CICLOALQUILO SUSTITUIDO POR OH, CARBOXI, ALQUILOXICARBONILO, ENTRE OTROS; n ES 0-3. SON COMPUESTOS PREFERIDOS (4R,10aR)-7-CLORO-4-METIL-1,2,3,4,10,10a-HEXAHIDRO-PIRAZINO[1,2-a]INDOL; (4R,10aR)-4,6,7-TRIMETIL-1,2,3,4,10,10a-HEXAHIDRO-PIRAZINO[1,2-a]INDOL, ENTRE OTROS; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y AL USO EN COMBINACION CON UN INHIBIDOR DE LIPASA COMO ORLISTAT. LOS COMPUESTOS SON LIGANDOS SELECTIVOS DEL RECEPTOR 5HT2 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS, ENCEFALITIS, MENINGITIS, DISFUNCION DE LA MOTILIDAD GASTROINTESTINAL, OBESIDAD
PE2001000749A 2000-07-31 2001-07-25 Derivados de piperazina como ligandos del receptor 5ht2 PE20020366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00116517 2000-07-31

Publications (1)

Publication Number Publication Date
PE20020366A1 true PE20020366A1 (es) 2002-05-17

Family

ID=8169405

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000749A PE20020366A1 (es) 2000-07-31 2001-07-25 Derivados de piperazina como ligandos del receptor 5ht2

Country Status (20)

Country Link
US (4) US20020035110A1 (es)
EP (1) EP1325008B1 (es)
JP (1) JP4180365B2 (es)
KR (1) KR100539139B1 (es)
CN (1) CN1277828C (es)
AR (1) AR030306A1 (es)
AT (1) ATE305933T1 (es)
AU (2) AU8395501A (es)
BR (1) BR0112918A (es)
CA (1) CA2417106C (es)
DE (1) DE60113865T2 (es)
DK (1) DK1325008T3 (es)
ES (1) ES2250459T3 (es)
GT (1) GT200100155A (es)
MX (1) MXPA03000906A (es)
PA (1) PA8523601A1 (es)
PE (1) PE20020366A1 (es)
UY (1) UY26863A1 (es)
WO (1) WO2002010169A1 (es)
ZA (1) ZA200300525B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
WO2003082333A1 (fr) * 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10320780A1 (de) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20050032930A1 (en) * 2003-07-02 2005-02-10 Christian Jackson Inkjet ink
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
EP2287303B1 (en) 2004-11-12 2014-07-02 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
ATE514698T1 (de) 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2006129826A1 (ja) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
RU2008116844A (ru) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4
AU2006308635A1 (en) * 2005-10-14 2007-05-10 H. Lundbeck A/S Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
CN101291662A (zh) 2005-10-21 2008-10-22 诺瓦提斯公司 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
WO2007065820A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (fr) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Dérivé diarylcétimine
ZA200904972B (en) 2007-01-16 2010-09-29 Ipintl Llc Novel composition for treating metabolic syndrome
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EP2134684B1 (en) * 2007-04-16 2017-08-02 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
US8207165B2 (en) 2008-03-28 2012-06-26 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US8440739B2 (en) * 2008-04-28 2013-05-14 Kuraray Noritake Dental Inc. Dental composition and composite resin
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
US8592457B2 (en) 2008-10-30 2013-11-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
FI122466B (fi) * 2009-08-21 2012-01-31 Hollming Oy Menetelmä työstettävän metallikappaleen kuumentamiseksi ja induktiokuumennustyökalu
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RS55532B1 (sr) 2012-03-16 2017-05-31 Vitae Pharmaceuticals Inc Modulatori jetrenog x receptora
LT2825541T (lt) 2012-03-16 2016-12-27 Vitae Pharmaceuticals, Inc. Kepenų x receptoriaus moduliatoriai
TWI579274B (zh) * 2012-04-20 2017-04-21 龍馬躍公司 製備１－芳基－５－烷基吡唑化合物的改良方法
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
SG11201508653QA (en) * 2013-04-23 2015-11-27 Esteve Labor Dr PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
MX2015014905A (es) * 2013-04-23 2016-03-07 Esteve Labor Dr Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
MX2016009588A (es) 2014-01-24 2017-05-15 Tp Therapeutics Inc Macrociclos de diarilo como moduladores de la proteina quinasa.
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
CA2989456C (en) 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
KR102623734B1 (ko) 2015-07-06 2024-01-10 터닝 포인트 테라퓨틱스, 인크. 디아릴 매크로사이클 다형체
RU2019114228A (ru) 2016-10-14 2020-11-16 Тес Фарма С.Р.Л. ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652018A (en) * 1900-02-15 1900-06-19 John C Duner Gate.
US3317524A (en) 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
DE2162422A1 (de) 1971-12-16 1973-06-20 Merck Patent Gmbh Pyrazinoindol-derivate und verfahren zu ihrer herstellung
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
SK106395A3 (en) 1993-03-01 1995-12-06 Merck Sharp & Dohme Treating and treatment or prevention of mental diseases
US5576319A (en) 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
US5622950A (en) 1993-03-01 1997-04-22 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
JP2000169475A (ja) 1998-07-24 2000-06-20 Dai Ichi Seiyaku Co Ltd ピラゾ―ル誘導体およびその塩
JP2002532504A (ja) * 1998-12-17 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション ５−ｈｔ２ｃ作動薬である２，３，４，４ａ−テトラヒドロ−１ｈ−ピラジノ（１，２−ａ）キノキサリン−５（６ｈ）−オン誘導体
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
WO2002010169A1 (en) * 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives

Also Published As

Publication number Publication date
US20070106076A1 (en) 2007-05-10
MXPA03000906A (es) 2005-02-24
UY26863A1 (es) 2002-01-31
US7253281B2 (en) 2007-08-07
US20020035110A1 (en) 2002-03-21
AR030306A1 (es) 2003-08-20
WO2002010169A1 (en) 2002-02-07
PA8523601A1 (es) 2002-10-24
DK1325008T3 (da) 2006-02-13
DE60113865T2 (de) 2006-07-20
GT200100155A (es) 2002-05-16
DE60113865D1 (de) 2006-02-16
CA2417106A1 (en) 2002-02-07
ES2250459T3 (es) 2006-04-16
CN1452622A (zh) 2003-10-29
KR100539139B1 (ko) 2005-12-26
AU2001283955B2 (en) 2006-05-18
CN1277828C (zh) 2006-10-04
US20030216401A1 (en) 2003-11-20
US20050239789A1 (en) 2005-10-27
CA2417106C (en) 2007-09-18
AU8395501A (en) 2002-02-13
US6933387B2 (en) 2005-08-23
JP2004505085A (ja) 2004-02-19
KR20030020954A (ko) 2003-03-10
ATE305933T1 (de) 2005-10-15
JP4180365B2 (ja) 2008-11-12
EP1325008B1 (en) 2005-10-05
EP1325008A1 (en) 2003-07-09
BR0112918A (pt) 2003-07-01
ZA200300525B (en) 2004-04-20

Similar Documents

Publication Publication Date Title
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
UY28150A1 (es) Agentes terapeuticos
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
CY1115606T1 (el) Ετεροκυκλικες ενωσεις, μεθοδοι κατασκευης αυτων και χρηση αυτων στη θεραπεια
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
ECSP056097A (es) Antagonistas del receptor cgrp
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
UY27551A1 (es) Derivados de benzotiazol
PE20021043A1 (es) DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2
PE20091371A1 (es) Inhibidores de hsp90
PE20030847A1 (es) Aza-arilpiperazinas como ligandos del receptor 5ht2
CO5590924A2 (es) Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6
UY25300A1 (es) Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia
AR013153A1 (es) Derivados de 2-arildihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados, y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n.
PE20010575A1 (es) Derivados de indol y su uso como ligandos del receptor 5ht2
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载